Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | AKT1 | P31749 | 1/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20231388 | 0.98 | NAMPT (0.39) | NAMPTTSHRALDH1A1MAPTAKT1 | |
| SCHEMBL20231390 | 0.98 | NAMPT (0.39) | NAMPTTSHRALDH1A1MAPTAKT1 | |
| SCHEMBL20231215 | 0.98 | NAMPT (0.39) | NAMPTTSHRALDH1A1MAPTAKT1 | |
| SCHEMBL13331628 | 0.98 | NAMPT (0.39) | NAMPTTSHRALDH1A1MAPTAKT1 | |
| SCHEMBL20231387 | 0.98 | NAMPT (0.39) | NAMPTTSHRALDH1A1MAPTAKT1 | |
| SCHEMBL20230959 | 0.92 | EPHX2 (0.38) | NAMPTTSHRALDH1A1MAPTAKT1 | |
| SCHEMBL20231225 | 0.92 | NAMPT (0.37) | NAMPTTSHRALDH1A1AKT1 | |
| SCHEMBL20231698 | 0.90 | EPHX2 (0.40) | NAMPTTSHRALDH1A1MAPTAKT1 | |
| SCHEMBL11514362 | 0.88 | LMNA (0.37) | TSHRALDH1A1MAPTMCL1LMNA | |
| SCHEMBL20231193 | 0.88 | TSHR (0.40) | NAMPTTSHRALDH1A1AKT1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11834460-B2 | Imide-based modulators of proteolysis and associated methods of use | YALE UNIVERSITY (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834460-B2 | Imide-based modulators of proteolysis and associated methods of use | YALE UNIVERSITY (US) | 2023-12-05 | — | — | US | disclosed |
| EP-3689868-B1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS INC (US) | 2023-09-27 | — | — | EP | disclosed |
| EP-3423111-B1 | COMPOUND, PROCESS FOR ITS PREPARATION, A PHARMACEUTICAL SOLUTION CONTAINING THE COMPOUND, A METHOD OF DETERMINING THE PRESENCE OF CANCER, A KIT FOR CANCER DETECTION, AND THE OF HYDROLYSIS OF THE COMPOUND FOR THE DETECTION OF CANCER | INST BIOTECHNOLOGII I MEDYCYNY MOLEKULARNEJ (PL) | 2023-08-16 | — | — | EP | disclosed |
| US-11707452-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20230183209-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS, INC. (US) | 2023-06-15 | — | — | US | disclosed |
| US-7517875-B2 | Piperidine derivatives having CCR3 antagonism | TEIJIN LIMITED (JP) | 2009-04-14 | — | — | US | disclosed |
| US-7488752-B2 | nor-seco himbacine derivatives; thrombosis, anticoagulants, anticancer agents; antiinflammatory agents; anticholesterol agents; cardiovascular disorders; antiarrhythmia agents; antiischemic agents; strokes; antiarthritic agents | SCHERING CORPORATION (US) | 2009-02-10 | — | — | US | disclosed |
| EP-1944300-A2 | Prodrugs of aspartyl protease inhibitors | Vertex Pharmaceuticals Incorporated (US) | 2008-07-16 | — | — | EP | disclosed |
| EP-0933372-B1 | Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors | VERTEX PHARMA (US) | 2007-12-26 | — | — | EP | disclosed |
| US-20070197628-A1 | Cannabinoid receptor modulators | INTERVET INTERNATIONAL B.V. (NL) | 2007-08-23 | — | — | US | disclosed |
| US-6667341-B2 | Amidomethyl esters, carbonylmercaptomethyl esters, keto-containing esters, amidomethyl thioesters, amidomethyl amides, and methylene dithioesters; anticancer agents, hemological disorders, and inherited metabolic disorders | BEACON LABORATORIES, INC. | 2003-12-23 | — | — | US | disclosed |
| US-20030171409-A1 | Novel delta dicarbonyl compounds and methods for using the same | BEACON LABORATORIES, INC, A DELAWARE CORPORATION | 2003-09-11 | — | — | US | disclosed |
| US-6562995-B1 | Amidomethyl esters, carbonylmercaptomethyl esters, keto-containing esters, amidomethyl thioesters, amidomethyl amides, and methylene dithioesters are disclosed. The novel compounds have two carbonyl groups connected by a linking moiety having | BEACON LABORATORIES, INC. | 2003-05-13 | — | — | US | disclosed |
| US-20020137775-A1 | Novel delta dicarbonyl compounds and methods for using the same | ERRANT GENE THERAPEUTICS, LLC | 2002-09-26 | — | — | US | disclosed |
| EP-1216986-A2 | Novel delta dicarbonyl compounds and methods for using same | Beacon Laboratories, Inc. (US) | 2002-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183209-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | CRBN, CBL, MDM2 | NAMPT 4289/4885TSHR 3772/4885ALDH1A1 3671/4885 |
| US-20030171409-A1 | Novel delta dicarbonyl compounds and methods for using the same | HCCS, CPS1, ACAA2 | NAMPT 1079/4885TSHR 3687/4885ALDH1A1 937/4885 |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | NAMPT 4757/4885TSHR 3456/4885ALDH1A1 2211/4885 |
| US-20070197628-A1 | Cannabinoid receptor modulators | CNR1, CNR2, GPR18 | NAMPT 2741/4885TSHR 681/4885ALDH1A1 1999/4885 |
| US-20020137775-A1 | Novel delta dicarbonyl compounds and methods for using the same | HCCS, CPS1, ACAA2 | NAMPT 1079/4885TSHR 3687/4885ALDH1A1 937/4885 |
| US-11707452-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | UCHL1, ADRM1, CRBN | NAMPT 4476/4885TSHR 4583/4885ALDH1A1 2567/4885 |
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | CRBN, MDM2, VHL | NAMPT 4168/4885TSHR 3794/4885ALDH1A1 3688/4885 |
| US-11834460-B2 | Imide-based modulators of proteolysis and associated methods of use | CRBN, MDM2, UBE2N | NAMPT 4018/4885TSHR 3257/4885ALDH1A1 3412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.